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Background: Aggressive curettage has been well established for the treatment of giant cell tumors (GCTs) of the
bone. The purpose of this study was to review our experience and evaluate the role of different implant materials
in patients with GCTs of the extremities after aggressive curettage.
Methods: A total of 119 patients with GCTs of the long bone were treated at the First Affiliated Hospital of Sun
Yat-Sen University between 2004 and 2009. We excluded patients presenting metastases, recurrent tumors, and soft
tissue involvement and those with Jaffe pathological grade III. The remaining 65 patients were treated with aggressive
curettage using a bone graft or bone cement to fill the cavity. The recurrence rates and functional scores associated
with the different fillings were analyzed.
Results: Aggressive curettage and bone grafting was performed in 34 cases (52.3%), and aggressive curettage with
bone cement was performed in 31 cases (47.7%). The overall recurrence rate after the aggressive intralesional
procedures was 35.3% with bone grafting and 12.9% when bone cement was used as an adjuvant filling. The
recurrence rate following aggressive curettage and bone grafting was higher than that following aggressive curettage
with cement (p = 0.038). The Musculoskeletal Tumor Society (MSTS) score for bone graft patients was 91.1%, which was
significantly lower than that for patients treated with bone cement (94.7%).
Conclusions: The use of bone cement was associated with a significantly lower recurrence rate than bone grafting
following aggressive intralesional curettage to treat benign giant cell tumors of the long bone. Better MSTS functional
results were also observed in the bone cement group compared to the bone graft group.
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Giant cell tumors (GCTs) are primary benign bone tu-
mors with invasive and potentially malignant character-
istics [1-3]. Intralesional curettage is the main surgical
treatment option [4,5]. After curettage, filling the cavity
with bone grafts or cement is commonly performed to
provide structural support and prevent collapse [6]. Pre-
vious studies have shown that using bone cement as a
filler can significantly reduce the relapse rate after curet-
tage [7-9]. In recent years, with the application of ag-
gressive curettage technology, which is characterized by* Correspondence: shenjingnan@126.com
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the giant cell tumor recurrence rate has been well con-
trolled, and there is a new argument regarding the best
type of implant material to use after aggressive curettage
[10-12]. It is well known that the GCT outcome may
differ according to many factors, including the presence
of metastatic disease at diagnosis, pathological fracture,
soft tissue involvement, and anatomical site [7,13,14].
Therefore, it is very difficult to make a reliable assess-
ment regarding the role of different implant materials,
and it is important to assess the role of different implant
materials in a group of patients with the same or similar
clinical conditions.
The aim of this study was to retrospectively review our
experience with GCTs in patients with similar clinical. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Typical radiograph of GCT of the long bone.
Anteroposterior radiograph shows a lytic lesion in the distal tibia (A)
and proximal tibia (C). Anteroposterior radiograph showing the
results after agreessive curettage and filling the bone defect with
bone grafts (B) and bone cement (D).
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plant materials to local control and functional results.
Methods
Patient selection
A total of 119 patients with GCTs of the long bone were
treated at the First Affiliated Hospital of Sun Yat-Sen
University between 2004 and 2009. The patient selec-
tion criteria for this retrospective study were as follows:
no previous treatment, no metastases at diagnosis, no
pathological fracture, no soft tissue involvement, Jaffe
pathological grade I or II [15], and underwent aggres-
sive curettage. Sixty-four cases were excluded, and the
remaining 65 cases constituted the group included in
the current study. Then, the patients were divided into
two groups according to the different local implant ma-
terials: Group 1, 34 patients who underwent aggressive
curettage and bone grafting (allograft and/or autograft);
and Group 2, who underwent aggressive curettage with
bone cement fillings. This study was approved by First
Affiliated Hospital of Sun Yat-Sen University ethics
committee to access patient data for clinical research.
Preoperative imaging and pathological examination and
evaluation
The imaging procedures included preoperative antero-
posterior and lateral X-ray examinations, MRI of the
ipsilateral long bone using 1.5 T and 3.0 T supercon-
ductive MR units (Magnetom Vision, Magnetom Trio
Tim, Siemens, Medical System, Erlangen, Germany),
and a preoperative anteroposterior chest X-ray exa-
mination. Axial and coronal or sagittal T1WI (TR 420–
600 ms and TE 12–20 ms) and T2WI (TR 2500–4500 ms
and TE 80–120 ms) sequences were used. The scan-
ning slice thickness was 4 mm with a 1 mm interval.
Two experienced radiologists independently observed
and recorded the X-ray and MRI findings of the
giant cell tumors and agreed upon a diagnosis. The
imaging findings included the integrity of the bone
shell, with or without a soft tissue mass, and with or
without lung metastases on the chest X-ray film.
Histological sections and records were available in
all cases and were reviewed and confirmed by two
experienced pathologists.
Tumor volume measurement
The anteroposterior and mediolateral maximum diame-
ters of the tumors were measured on preoperative axial
MR images. The longitudinal maximum diameters of tu-
mors were measured on preoperative coronal or sagittal
MR images in the long bones. The tumor volume was cal-
culated using the formula as follows: Tumor volume =Π/
6 (anteroposterior maximum diameter × mediolateralmaximum diameter × longitudinal maximum diameter),
according to the methods used by Bieling P et al. [16].
Treatment protocol
Local treatment consisted of aggressive curettage (high-
speed burring, alcohol and iodine tincture as adjuvant)
and bone grafting (Figure 1B) or aggressive curettage
with cement (Figure 1D). The type of local treatment was
chosen for each patient based on careful consideration of
data and after a discussion with radiotherapists, surgeons,
and medical oncologists. The choice of local treatment
was tailored to each patient’s characteristics: age; tumor
site, size, and grade; and expected level of function.
Postoperative follow-up
All patients were followed up to review clinical func-
tional results and perform an X-ray examination at
3 months, 6 months, 9 months, and 12 months after the
clinical operation and continued to be followed up every
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ety score, developed by Enneking, was used to assess
functional results [17]. Local tumor recurrence was de-
termined by X-ray, and MRI was chosen if the clinical
manifestations or X-ray findings could not confirm local
tumor recurrence. All recurrent tumors were confirmed
by a second surgical pathology. The end of follow-up for
this study was the time of tumor recurrence.
Statistical analysis
The chi-square test was used to evaluate the statistical
association between two variables. The Kaplan–Meier
and log-rank methods were used to draw and evaluate
the significance of event-free survival curves. One-way
ANOVA was used to highlight different functional
results between the different implant materials. A diffe-
rence was considered statistically significant when the
P-value was less than 0.05. Statistical analyses were
performed using the Statistical Package for the Social
Sciences (SPSS), version 19.0 (SPSS Inc., Chicago, USA).
Results
Clinical appearance
Of the 65 patients in our study, 33 were male and 32
were female, with a mean age of 31.8 years (range: 18–
65 years). The tumor site was the proximal femur in 4
cases, the distal femur in 28 cases, the proximal tibia in
27 cases, the distal radius in 5 cases, and the distal tibia
in 1 case. The tumor volume ranged from 4 to 310 ml,
with an average of 68 ml. The Jaffe pathological grades
of the tumors were as follows: I, 14 cases; II, 51 cases.
The mean follow-up time was 38.8 months, ranging
from 6 to 84 months. At the scheduled follow-up visits,
49 patients (75.4%) had no evidence of disease, and 16
(24.6%) demonstrated local recurrence. The intervalFigure 2 The interval between surgery and local recurrence for the 1between surgery and local recurrence for the 16 patients
treated at our hospital ranged from 6 months to 5 years
(average, 19.8 months) postoperatively. Thirteen patients
(81.3%) had a local recurrence within 2 years after sur-
gery (Figure 2). Only 3 patients (18.7%) had a recurrence
after more than 2 years.
Event-free survival analysis
Univariate analyses, as shown in Table 1, were first per-
formed for all 65 patients. Sex, age, tumor site, tumor
volume, and pathological grade were not significant. The
rate of 3-year EFS was significantly lower for local treat-
ment with bone grafting compared to cement (64.7% vs.
87%, P = 0.038). In contrast to other studies, proximal
femur cases had the best prognosis (100%, 3-year EFS),
and the distal femur location had the worst (71.4%, 3-
year EFS). Even more interestingly, patients with a
tumor volume less than 50 ml had a worse 3-year EFS
(71.0%) than those with larger tumors (79.4%); this dif-
ference was not significant (P = 0.433). Although patients
with Jaffe pathological grade I had a higher 3-year EFS
than those of grade II, this difference was not significant
(P = 0.089). The Kaplan–Meier and log-rank life table
analyses also confirmed that local treatment with cement
was significantly associated with a higher probability of
better events and a better outcome (Figure 3).
Comparison of different adjuvant therapies
To further investigate the effects of different adjuvant
therapies for local control, we compared the clinical fea-
tures of different local treatments (Table 2). Of the 34
patients in the progressive curettage and bone grafting
group (Group 1), 17 were male and 17 were female. The
age ranged from 18 to 49 years old, with an average of
30.7 years. The tumor site was the proximal femur in 46 recurrene patients treated at our hospital.
Table 1 Analysis of clinic factors predicting 3-year event









male 33 25 75.8
female 32 24 75.0
Age(Yrs.) 0.616
≤30 33 24 72.7
>30 32 25 78.1
Site 0.75
Proximal femur 4 4 100.0
Distal femur 28 20 71.4
Proximal tibia 27 20 74.1
Distal radius 5 4 80.0
Distal tibia 1 1 100.0
Tumor volume(ml) 0.433
≤50 31 22 71.0
>50 34 27 79.4
Grade 0.089
I 14 13 92.9
II 51 36 70.6
Local treatment 0.038
Bone graft 34 22 64.7
Cement 31 27 87.1
Figure 3 Kaplan–Meier life table analysis of cumulative event free sur
treatment (p = 0.0264).
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13 cases, the distal radius in 5 cases, and the distal tibia
in 1 case. The tumor volume ranged from 4 to 185 ml,
with an average of 42 ml. The Jaffe pathological grades
were as follows: I, 10 cases; II, 24 cases. The follow-up
time was between 6 and 84 months, with an average of
37.7 months. Local tumor recurrence was evident in 12
patients in this group (35.3%). The tumor was detected
from 6 to 60 months (mean 17.9 months) after local
treatment.
Of the 31 patients in the progressive curettage and ce-
ment group (Group 2), 16 were male and 15 were female.
The age ranged from 19 to 65 years old, with an average
of 33.1 years. The tumor site was the proximal femur in 1
case, the distal femur in 16 cases, and the proximal tibia in
14 cases. The tumor volume ranged from 28 to 310 ml,
with an average of 96 ml. The Jaffe pathological grades
were as follows: I, 4 cases; II, 27 cases. The follow-up
period ranged from 12 to 72 months, with an average of
46.5 months. In this group, local recurrence was de-
tected in four patients (12.9%) at 12 to 54 months
(mean 20.4 months) after surgery.
Regarding the patient clinical features of the two
groups, one significant difference was tumor volume
(Table 2). In the bone graft group, tumor volume was
significantly smaller compared to the cement group (P <
0.001). The local recurrence rate of the bone graft group
was also higher compared to the cement group, and this
difference reached statistical significance (P < 0.05).
Different MRI manifestation in the two groups
Six patients have been underwent MRI examination during
follow up with an average of 9.8 months (6–14 months),vival survival of GCT patients according to different local
Table 2 Comparison of clinic data of 65 patients with GCT
according to different treatment group 1 vs group 2
Patient data Group 1 Group 2 P-value








Proximal femur 4 0
Distal femur 11 17
Proximal tibia 13 14
Distal radius 5 0










Figure 4 Different MRI findings between bone grafts and bone
cement group after agreessive curettage during follow up. The
coronal T1WI (A) and coronal fat-suppressed T2WI (B) showed that
the band signal around the area filled with bone cement. No similar
MRI findings in the bone grafting group (C and D).
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An abnormal banded signal around the area filled with
bone cement was found in the two cement group cases
(Figure 4A,B). Howerer, there was no similar MRI find-
ings in the bone grafting group (Figure 4C,D).
Comparison of the MSTS functional scores in the two
groups
Better functional results were observed following treat-
ment with cement compared to bone grafting. The mean
score in the cement group was 94.7 (SD 5.4), whereas it
was 91.1 (SD 7.5) after bone grafting. One-way ANOVA
showed a significant difference between the type of adju-
vant therapy and functional, outcome (P = 0.011).
Discussion
GCTs of the bone are aggressive and potentially malig-
nant primary bone tumors that often occur at the end of
the long bone in adults aged 20 ~ 40 years old [18,19].
These tumors are primarily composed of stromal cells
and multinucleated giant cells; the stromal cells are the
main tumor cell component in GCTs of the bone
[20,21]. According to microscopic morphological find-
ings, Jaffe created a pathological classification system forGCTs, including grades I-III. In the new bone tumor
classification released by the WHO in 2002, GCTs of the
bone were divided into GCTs and malignant GCTs. The
former are equivalent to grades I ~ II, and the latter is
equivalent to grade III.
Surgical treatment options include intralesional exci-
sion or segmental resection [7,14]. Curettage has a
higher recurrence rate [22,23], but it preserves adjacent
joint function. The ideal treatment of GCTs consists of
excising the tumor and sparing the joint. Therefore,
many scholars believe that GCTs should be treated using
curettage [24,25]. To avoid local recurrence, aggressive
curettage has been widely used and has achieved good
clinical results [12,14]. The recommended aggressive
curettage technique involves opening the bone through
a large cortical window that allows visualization of the
entire tumor cavity. After curettage is achieved, the cav-
ity is deepened with the use of high-speed burrs [14,26].
Various adjuvant therapies (including phenol and liquid
nitrogen) may be employed in conjunction with curet-
tage, and these most likely reduce the risk of recurrence
compared with curettage alone [19,25].
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cement or bone grafting [10]. The literature is divided as
to whether the bone defect should be filled using bone
grafts or cement. In the Scandinavian Sarcoma Group
multicenter study by Kivioja et al. [8], which involved
294 patients, filling the cavity with cement was shown to
be a prognostic factor. The recurrence rate was 20% for
filling with cement and 56% for intralesional surgery
without cementation (p = 0.001). Becker WT et al. [13]
has also reported that the use of bone cement as an ad-
juvant significantly reduces the recurrence rate following
intralesional treatment of benign giant cell tumors, and
it appears to be the therapy of choice for primary as well
as recurrent giant cell tumors of the bone. By contrast,
in the Canadian multicenter study by Turcotte et al.
[11], which involved 186 patients, the adjuvant method
or filling material was not significantly associated with
the risk of recurrence. By retrospectively reviewing the
records and images of 621 extremity GCT patients be-
tween 1989 and 2009, Niu X et al. [12] also concluded that
bone grafting did not affect local tumor control after ag-
gressive curettage and that the local recurrence rate was
11.1% if bone grafting was used. Similar results were also
reported by Errani C et al. [14]; although cement de-
creased local recurrence, the influence of adjuvants was
not statistically significant.
Many factors might influence the treatment outcome of
GCTs [7,13,27], and none of these studies were random-
ized. Therefore, the evaluation of prognostic factors and
the assessment of different local treatments may be af-
fected by selection bias. Errani C [14] stated that no pro-
spective randomized studies have shown the effects of
different methods of filling the cavity. However, the main
shortcoming of these retrospective reviews is the analysis
of patients over a long time period, over which many
changes in imaging studies, pathological examinations,
and surgical treatments occurred, altering the diagnostic
approach and treatment of patients with GCTs.
To avoid this problem, we used detailed patient selec-
tion criteria for this retrospective study performed for
2004–2009, including patients who underwent aggres-
sive curettage. The operative procedure was also limited
to three senior surgeons in our department. Our retro-
spective review attempted to identify prognostic factors
useful to evaluate the risk level for each patient and pos-
sibly determine the strategies of GCT treatment.
After the univariate analysis, no significant statistical
effect on the local recurrence rate was observed for gen-
der, age, tumor volume, or Jaffe grade. Only the type of
implant materials emerged as a significant factor. Bone
cement was shown to be more effective at treating GCT
compared with bone grafting. The Kaplan–Meier and log-
rank life table analysis also confirmed that local cement
treatment was significantly associated with a higherprobability of better events and a better outcome. Re-
garding our patients’ clinical features, the only signifi-
cant difference between the two groups was tumor
volume (Table 2); in the bone grafting group, tumor vol-
ume was significantly smaller compared to the cement
group (P < 0.001). Patients with small primary tumors
might have a better prognosis and be more likely to be
cured by bone grafting. However, bone grafting patients
with smaller tumors relapsed more often compared to
the cement group, which further suggests that bone ce-
ment is an effective adjuvant to treat GCT of the long
bone, even for larger tumors.
Similar to marginal excision, it is difficult to com-
pletely remove residual tumor cells in the inner wall of
the cavity using aggressive curettage, and there is still
the possibility of relapse. Compared with bone grafting,
bone cement can be combined with firmly scraping the
edges of the residual cavity. When bone cement solidi-
fies, it releases polymerizing heat reaching 80-90°C,
which has a high-temperature inactivation effect on the
residual cavity of the tumor [28,29]. These factors are
most likely the main reasons for the lower recurrence
rate with bone cement fillings compared to bone grafting.
We also found an abnormal banded signal around the area
filled with bone cement by MRI (Figure 4A,B), which
could reflect damage to the surrounding bone marrow
due to the high-temperature effect. Howerer, there was
no similar MRI findings in the bone grafting group
(Figure 4C,D).
In most cases, the tumor recurred during the first two
years (81.3%) after surgery in our series, which is con-
sistent with other studies [1,14], but the longest recur-
rence required 5 years to develop. Therefore, we suggest
that patients should be evaluated through at least the
5th year after the final surgery. The data also showed
that the GCT recurrence rates were 66.7% for bone
grafting and 50% for bone cement one year after surgery,
while they were 83.3% for bone grafting and 75% for
bone cement in the first two years. These data indicate
that the different implants and different postoperative
times may lead to differences in the tumor recurrence
rate following aggressive curettage of giant cell tumors
of the long bone.
In other studies, tumor location significantly affected
prognosis. Due to the difficulty associated with treatment,
the distal radius and proximal femur are associated with a
higher rate of local recurrence [14,30]. However, there
was no statistical correlation between tumor location
and prognosis in our series.
For giant cell tumors of the long bones, the theoretical
advantages of bone grafting, if the tumor does not re-
lapse, include the ability of autologous or allograft bone
to achieve bone healing, satisfactory recovery and no re-
visions. In contrast to our expectation, better functional
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the bone grafting group (P = 0.011) in our series. This
discrepancy may due to the early weight-bearing activ-
ities of cement group patients and the short follow-up
period during which bone cement-related complications,
such as osteoporosis, were observed less often.
The limitations of our study include the retrospective
analysis and the lack of random assignment of the type
implant material used due to the tailored choice made
according to each patient’s requirements.
Conclusion
In conclusion, we showed that the use of bone cement
in a group of patients with GCTs of the long bone re-
sulted in a lower local recurrence rate when compared
to bone graft patients following aggressive intralesional
curettage treatment. Better MSTS functional results
were also observed after bone cement compared to the
bone graft group. A prospective randomized study evalu-
ating the effects of different methods of filling the cavity
should be performed in the near future.
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